BTIG Maintains Buy on Bright Minds Biosciences, Lowers Price Target to $37
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and lowers the price target from $147 to $37.
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and lowers the price target from $147 to $37.